ReviewEuropean journal of nuclear medicine and molecular imaging2018
Current status of theranostics in prostate cancer.
Review in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.
- Diagnostic efficacy of [BMC cancer · 2024Pooled it
- PSMA-Targeting Positron Emission Agents for Imaging Solid Tumors Other Than Non-Prostate Carcinoma: A Systematic Review.International journal of molecular sciences · 2019Pooled it
- Clinical research analysis of [European journal of nuclear medicine and molecular imaging · 2026Article
- Preclinical evaluation ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- A New Labeling Method ofWorld journal of nuclear medicine · 2025Article
- PSMA-Targeted Radiolabeled Peptide for Imaging and Therapy in Prostate Cancer: Preclinical Evaluation of Biodistribution and Therapeutic Efficacy.International journal of molecular sciences · 2025Article
- Comparative Evaluation of (World journal of nuclear medicine · 2025Article
- JHU-2545 preferentially shields salivary glands and kidneys during PSMA-targeted imaging.European journal of nuclear medicine and molecular imaging · 2025Article
- Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Quantification of biochemical PSA dynamics after radioligand therapy with [EJNMMI physics · 2024Article
- Care Pathway at a Cancer Center for the Administration of Radiometabolic Therapy with 177Lu-PSMA in Patients with Metastatic Castration-resistant Prostate Cancer.Molecular imaging and radionuclide therapy · 2024Article
- Mechanisms and characteristics of subcapsular sinus macrophages in tumor immunity: a narrative review.Translational cancer research · 2023Review
- Development and Characterization ofInternational journal of molecular sciences · 2023Article
- Development of [European journal of nuclear medicine and molecular imaging · 2023Article
- Status ofWorld journal of urology · 2023Article
- Long-axial field-of-view PET/CT: perspectives and review of a revolutionary development in nuclear medicine based on clinical experience in over 7000 patients.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Review
- PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Pharmacological Optimization of PSMA-Based Radioligand Therapy.Biomedicines · 2022Review
- Theragnostic Radionuclide Pairs for Prostate Cancer Management:Biomedicines · 2022Review
- Advances in nuclear medicine-based molecular imaging in head and neck squamous cell carcinoma.Journal of translational medicine · 2022Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this review is to report on the current status of prostate-specific membrane antigen (PSMA)-directed theranostics in prostate cancer (PC) patients. The value of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.